Pharmaceutical Technology

DECEMBER 9, 2022

M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. Pharmaceutical Technology Excellence Rankings – The Verdict. Integrated analytical services for pharmaceuticals.

Development 130

Development Manufacturing Production Vaccination 130

Pharmaceutical Technology

SEPTEMBER 10, 2008

The first activities of the company concerned the pre-clinical toxicological testing of several new candidate molecules showing cytostatic activity, initially developed by a former research institute, as well as the breeding and supplying of laboratory animals.

In-Vitro 130

In-Vitro Genotoxicity In-Vivo Clinical Research 130

The Pharma Data

MARCH 25, 2021

SG is an antibody and topoisomerase inhibitor conjugate directed to the Trop-2 cell surface antigen, a protein frequently expressed in multiple types of epithelial tumors, including TNBC, where high expression is associated with poor survival and relapse. More information about ASCENT is available at [link]. Embryo-Fetal Toxicity.

Genotoxicity 52

Genotoxicity Genotype Containment Protein 52

The Pharma Data

APRIL 7, 2021

Today’s approval is the culmination of a multi-year development program and validates the clinical benefit of this important treatment in metastatic TNBC,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells.

HR 52

HR Genotype FDA Approval Genotoxicity 52

The Pharma Data

APRIL 14, 2021

Trodelvy is also being developed as an investigational treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. About Trodelvy.

Genotype 52

Genotype Containment FDA Approval Genotoxicity 52